Latest Biopharmaceuticals News

Page 20 of 20
Neurotech International has secured a $2.44 million R&D tax incentive refund, strengthening its cash position as it advances clinical trials for paediatric neurological disorders and prepares for regulatory submissions in FY2025.
Ada Torres
Ada Torres
31 Jan 2025
Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.
Ada Torres
Ada Torres
30 Jan 2025
Radiopharm Theranostics has secured key ethics approvals to expand its clinical trial portfolio, completed significant preclinical milestones, and raised A$8 million through a strategic placement, while maintaining its cash runway to mid-2026.
Ada Torres
Ada Torres
30 Jan 2025
NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.
Victor Sage
Victor Sage
30 Jan 2025
Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.
Victor Sage
Victor Sage
28 Jan 2025
Telix Pharmaceuticals has finalized its acquisition of RLS (USA) Inc., significantly expanding its radiopharmaceutical footprint across the United States with a network of over 30 radiopharmacies.
Victor Sage
Victor Sage
28 Jan 2025
Zelira Therapeutics has received a fourth funding tranche, bringing total investment to US$3.25 million to support FDA clinical trials of its HOPE® 1 cannabinoid medicine targeting irritability in autism spectrum disorder and Phelan-McDermid Syndrome.
Victor Sage
Victor Sage
28 Jan 2025
Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.
Victor Sage
Victor Sage
24 Jan 2025
Invex Therapeutics reports encouraging results from its collaboration with Tessara Therapeutics, showing Exenatide’s potential to improve neuronal survival in a 3D human brain model of Alzheimer's disease. The company maintains a stable cash position while exploring new neurological partnerships.
Victor Sage
Victor Sage
22 Jan 2025
Dimerix has reached a key milestone by enrolling the first paediatric patient aged 12-17 in its ACTION3 Phase 3 trial for DMX-200, advancing its potential treatment for childhood FSGS kidney disease.
Victor Sage
Victor Sage
16 Jan 2025

Browse the archive

Full archive